Cerenome, Inc. CNSY
0.95 USD +0.18 (+23.32%)
Regular-session close
0.94 -0.01 -1.07%
Pre-market · Nov 16, 5:21 AM ET
0.813 Day range 1.18
0.43 52-week range 19.00
- YTD
- -92.55%
- 1 year
- -92.69%
News
zacks.com Cerenome (CNSY) Reports Q3 Loss, Beats Revenue Estimates Cerenome (CNSY) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $1 per share a year ago.benzinga.com Cerenome Q3 EPS $(1.14) Misses $(0.95) Estimate, Sales $722.000K Miss $920.333K Estimate Cerenome (NASDAQ:CNSY) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(0.95) by 20 percent. This is a 10.68 percent decrease over losses of $(1.03) per…
globenewswire.com Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company advancing an integrated platform that combines precision diagnostics,…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Cerenome (NASDAQ:CNSY) shares rose 39.5% to $1.07 during Friday's regular session. The market value of their outstanding shares is at $5.8 million. As per the press release, Q3 earnings came…
globenewswire.com Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16 HOUSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence,…
globenewswire.com Cerenome Appoints Director Ron Andrews as Chief Business Officer HOUSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence,…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Curis (NASDAQ:CRIS) shares moved upwards by 61.8% to $1.16 during Wednesday's regular session. The market value of their outstanding shares is at $1.7 million. Lyell Immunopharma…benzinga.com CNSide Diagnostics Inks National In-Network Laboratory Ancillary Provider With Aetna Health Plans CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), announced today that it has entered into a national in-network laboratory ancillary
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Curis (NASDAQ:CRIS) stock increased by 25.6% to $0.83 during Tuesday's regular session. The company's market cap stands at $1.6 million. Pasithea Therapeutics (NASDAQ:KTTA) shares increased…benzinga.com Cerenome To Report Poster Presentation Of Interim Data From Its Current ReSPECT-LMM Multidose Trial Of REYOBIQ At 31st Annual Meeting And Education Day Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence today announced that a poster presentation of…
benzinga.com Cerenome Presents New Preclinical Data At 16th Biennial Rivkin Ovarian Cancer Research Symposium Regarding Immunomodulatory Properties Of REYOBIQ Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company") today announced that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging
